<p>隨着全球市場經歷積極的企業盈利和上升的消費者通脹，科技行業繼續吸引關注，納斯達克綜合指數等指數創下新高。在這個動態環境中，識別高增長科技股需要尋找那些不僅展現出強勁財務表現，而且在經濟波動中表現出韌性和適應能力的公司。</p>
<h3>全球十大高增長科技公司</h3>
<table>
<thead>
<tr>
<th>名稱</th>
<th>收入增長</th>
<th>盈利增長</th>
<th>增長評級</th>
</tr>
</thead>
<tbody>
<tr>
<td>金電路電子</td>
<td>20.76%</td>
<td>25.89%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>上海華測導航技術</td>
<td>24.51%</td>
<td>23.48%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Pharma Mar</td>
<td>26.67%</td>
<td>43.29%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>盛宜電子</td>
<td>26.23%</td>
<td>37.40%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>eWeLLLtd</td>
<td>24.95%</td>
<td>24.40%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>KebNi</td>
<td>20.56%</td>
<td>94.46%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>全球安全專家</td>
<td>20.56%</td>
<td>28.04%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>CARsgen Therapeutics Holdings</td>
<td>81.53%</td>
<td>96.08%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Elliptic Laboratories</td>
<td>36.33%</td>
<td>78.99%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>JNTC</td>
<td>55.45%</td>
<td>94.52%</td>
<td>★★★★★★</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們全球高增長科技和人工智能股票篩選器中的 745 只股票的完整列表。</p>
<p>讓我們回顧一些我們篩選股票中的顯著選擇。</p>
<h2>上海電影 (SHSE:601595)</h2>
<p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> 上海電影有限公司在中國從事電影發行和放映活動，市值為 140.3 億人民幣。</p>
<p><strong>運營：</strong> 該公司主要通過在中國的電影發行和放映活動產生收入。其市值為 140.3 億人民幣，專注於娛樂行業。</p>
<p>儘管上海電影去年盈利下降 20.4%，但預計將迎來強勁復甦，年盈利增長預計為 35.2%。這一增長率超過了中國市場 23.3% 的平均水平，突顯了公司在娛樂行業的韌性和潛力。隨着研發投資大幅集中於創新內容創作，顯著的支出增強了其在快速變化的行業環境中的競爭優勢，上海電影展現出良好的發展軌跡。該公司還受益於 4500 萬人民幣的可觀一次性收益，提升了其財務狀況，為未來擴張和更具活力的市場參與做好準備。</p>
<ul>
<li>在我們的健康報告中更詳細地瞭解上海電影的潛力。</li>
<li>查看我們的歷史業績報告，以獲取上海電影過去表現的見解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/979b42f0-003e-4755-b0af-db38fd491944/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/979b42f0-003e-4755-b0af-db38fd491944/chart/revenue-and-expenses-breakdown"/></p>
<p>截至 2025 年 7 月的 SHSE:601595 收入和支出明細</p>
<h2>HAND 企業解決方案 (SZSE:300170)</h2>
<p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> HAND 企業解決方案有限公司在中國提供 ERP 實施諮詢服務，市值為 190.2 億人民幣。</p>
<p><strong>運營：</strong> 該公司專注於在中國提供 ERP 實施諮詢服務，致力於為客户提供量身定製的解決方案，以優化其業務流程，為其收入模式做出重要貢獻。</p>
<p>HAND 企業解決方案展現出強勁的增長軌跡，預計年盈利將激增 26.3%，超過中國市場 23.3% 的平均水平。考慮到該公司最近轉向盈利，這一表現尤為顯著，反映了其運營效率和市場適應能力。該公司還堅定致力於股東回報，最近確認分紅，每股現金分紅為 0.48 元人民幣。此外，HAND 在研發方面的戰略重點顯而易見，分配了大量資源用於創新，確保其在動態科技環境中保持競爭力。</p>
<ul>
<li>在我們的綜合健康報告中深入瞭解 HAND 企業解決方案的複雜性。</li>
<li>通過我們的詳細歷史業績報告評估 HAND 企業解決方案的過去表現。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/c577163e-dd8c-4766-90c7-04ff8893cfda/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/c577163e-dd8c-4766-90c7-04ff8893cfda/chart/revenue-and-expenses-breakdown"/></p>
<p>截至 2025 年 7 月的 SZSE:300170 收入和支出明細</p>
<h2>華蘭生物疫苗 (SZSE:301207)</h2>
<p><strong>Simply Wall St 增長評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> 華蘭生物疫苗有限公司專注於中國疫苗的研發、生產和銷售，市值為 111.8 億人民幣。</p>
<p><strong>運營：</strong> 該公司主要通過其疫苗產品產生收入，利用其在研發方面的專業知識。其對中國市場的關注得到了強大的生產和銷售基礎設施的支持。</p>
<p>華蘭生物疫苗正處於一個轉型階段，預計年收入增長 36.1%，超過中國市場 12.4% 的擴張率。儘管去年面臨顯著的盈利下滑和 17.9% 的較低利潤率（相比之前的 35%），公司的戰略調整旨在增強治理和運營靈活性。這一積極的做法得到了積極的研發投資策略的支持，確保華蘭在生物科技領域保持創新的前沿。預計年盈利將激增 49.8%，這些舉措可能使華蘭在競爭環境中處於有利地位。</p>
<ul>
<li>通過閲讀我們的健康報告，深入瞭解華蘭生物疫苗的表現。</li>
<li>檢查華蘭生物疫苗的過去表現報告，以瞭解其過去的表現。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/85c1c8b5-f8c4-4232-83d4-2d75422da5a7/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/85c1c8b5-f8c4-4232-83d4-2d75422da5a7/chart/earnings-and-revenue-growth"/></p>
<p>深交所：301207 截至 2025 年 7 月的收益和收入增長</p>
<h2>總結</h2>
<ul>
<li>點擊此鏈接深入瞭解我們全球高增長科技和人工智能股票篩選器中的 745 家公司。</li>
<li>這些公司是否是您投資策略的一部分？使用 Simply Wall St 將您的持股整合到一個投資組合中，並通過我們全面的分析工具獲得洞察。</li>
<li>Simply Wall St 是您解鎖全球市場趨勢的關鍵，是一款面向前瞻性投資者的免費用户友好應用程序。</li>
</ul>
<h2>尋找新視角？</h2>
<ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>用顯示強勁增長潛力的公司來充實您的投資組合，這些公司得到了分析師和管理層的樂觀展望支持。</li>
<li>尋找現金流潛力良好但交易價格低於其公允價值的公司。</li>
</ul>
<p><em>這篇文章由 Simply Wall St 撰寫，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，僅使用無偏見的方法，我們的文章不構成財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>

華蘭生物

<p>隨着全球市場看到企業盈利向好和消費者通脹上升，科技行業備受關注，納斯達克綜合指數創下新高。關鍵的高增長科技公司包括金環電子、上海華測導航技術和 Pharma Mar，展現出強勁的收入和盈利增長。像上海電影和 HAND 企業解決方案這樣的顯著選擇表現出韌性和適應能力，預計盈利增長將超過市場平均水平。華蘭生物疫苗也在尋求顯著增長，專注於研發和運營改進。投資者被鼓勵探索科技行業中的這些機會</p>

<p>As global markets experience a mix of positive corporate earnings and rising consumer inflation, the tech sector continues to draw attention with indices like the Nasdaq Composite reaching new highs. In this dynamic environment, identifying high-growth tech stocks involves looking for companies that not only demonstrate robust financial performance but also show resilience to economic fluctuations and adaptability in the face of evolving market conditions.</p>
<div class="lb-trans"><p>隨着全球市場經歷積極的企業盈利和上升的消費者通脹，科技行業繼續吸引關注，納斯達克綜合指數等指數創下新高。在這個動態環境中，識別高增長科技股需要尋找那些不僅展現出強勁財務表現，而且在經濟波動中表現出韌性和適應能力的公司。</p>
</div><h3>Top 10 High Growth Tech Companies Globally</h3>
<div class="lb-trans"><h3>全球十大高增長科技公司</h3>
</div><table>
<thead>
<tr>
<th>Name</th>
<th>Revenue Growth</th>
<th>Earnings Growth</th>
<th>Growth Rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gold Circuit Electronics</td>
<td>20.76%</td>
<td>25.89%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Shanghai Huace Navigation Technology</td>
<td>24.51%</td>
<td>23.48%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Pharma Mar</td>
<td>26.67%</td>
<td>43.29%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Shengyi Electronics</td>
<td>26.23%</td>
<td>37.40%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>eWeLLLtd</td>
<td>24.95%</td>
<td>24.40%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>KebNi</td>
<td>20.56%</td>
<td>94.46%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Global Security Experts</td>
<td>20.56%</td>
<td>28.04%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>CARsgen Therapeutics Holdings</td>
<td>81.53%</td>
<td>96.08%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Elliptic Laboratories</td>
<td>36.33%</td>
<td>78.99%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>JNTC</td>
<td>55.45%</td>
<td>94.52%</td>
<td>★★★★★★</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>名稱</th>
<th>收入增長</th>
<th>盈利增長</th>
<th>增長評級</th>
</tr>
</thead>
<tbody>
<tr>
<td>金電路電子</td>
<td>20.76%</td>
<td>25.89%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>上海華測導航技術</td>
<td>24.51%</td>
<td>23.48%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Pharma Mar</td>
<td>26.67%</td>
<td>43.29%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>盛宜電子</td>
<td>26.23%</td>
<td>37.40%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>eWeLLLtd</td>
<td>24.95%</td>
<td>24.40%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>KebNi</td>
<td>20.56%</td>
<td>94.46%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>全球安全專家</td>
<td>20.56%</td>
<td>28.04%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>CARsgen Therapeutics Holdings</td>
<td>81.53%</td>
<td>96.08%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Elliptic Laboratories</td>
<td>36.33%</td>
<td>78.99%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>JNTC</td>
<td>55.45%</td>
<td>94.52%</td>
<td>★★★★★★</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 745 stocks from our Global High Growth Tech and AI Stocks screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們全球高增長科技和人工智能股票篩選器中的 745 只股票的完整列表。</p>
</div><p>Let's review some notable picks from our screened stocks.</p>
<div class="lb-trans"><p>讓我們回顧一些我們篩選股票中的顯著選擇。</p>
</div><h2>Shanghai Film (SHSE:601595)</h2>
<div class="lb-trans"><h2>上海電影 (SHSE:601595)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Shanghai Film Co., Ltd. is involved in film distribution and screening activities in China, with a market cap of CN¥14.03 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 上海電影有限公司在中國從事電影發行和放映活動，市值為 140.3 億人民幣。</p>
</div><p><strong>Operations:</strong> The company generates revenue primarily from film distribution and screening activities within China. It operates with a market cap of CN¥14.03 billion, focusing on the entertainment sector.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司主要通過在中國的電影發行和放映活動產生收入。其市值為 140.3 億人民幣，專注於娛樂行業。</p>
</div><p>Shanghai Film, despite recent challenges with a 20.4% drop in earnings last year, is poised for a robust recovery with projected annual earnings growth of 35.2%. This growth rate outpaces the Chinese market's average of 23.3%, underscoring the company's resilience and potential in the entertainment sector. With R&amp;D investments sharply focused on innovative content creation, evidenced by their significant spendings which bolstered their competitive edge in a rapidly evolving industry landscape, Shanghai Film demonstrates a promising trajectory. The firm also benefits from substantial one-off gains amounting to CN¥45M, enhancing its financial standing as it gears up for future expansions and more dynamic market engagement.</p>
<div class="lb-trans"><p>儘管上海電影去年盈利下降 20.4%，但預計將迎來強勁復甦，年盈利增長預計為 35.2%。這一增長率超過了中國市場 23.3% 的平均水平，突顯了公司在娛樂行業的韌性和潛力。隨着研發投資大幅集中於創新內容創作，顯著的支出增強了其在快速變化的行業環境中的競爭優勢，上海電影展現出良好的發展軌跡。該公司還受益於 4500 萬人民幣的可觀一次性收益，提升了其財務狀況，為未來擴張和更具活力的市場參與做好準備。</p>
</div><ul>
<li>Take a closer look at Shanghai Film's potential here in our health report.</li>
<li>Review our historical performance report to gain insights into Shanghai Film's's past performance.</li>
</ul>
<div class="lb-trans"><ul>
<li>在我們的健康報告中更詳細地瞭解上海電影的潛力。</li>
<li>查看我們的歷史業績報告，以獲取上海電影過去表現的見解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/979b42f0-003e-4755-b0af-db38fd491944/chart/revenue-and-expenses-breakdown" alt="" original-src="https://images.simplywall.st/company/979b42f0-003e-4755-b0af-db38fd491944/chart/revenue-and-expenses-breakdown"/></p>
<p>SHSE:601595 Revenue and Expenses Breakdown as at Jul 2025</p>
<div class="lb-trans"><p>截至 2025 年 7 月的 SHSE:601595 收入和支出明細</p>
</div><h2>HAND Enterprise Solutions (SZSE:300170)</h2>
<div class="lb-trans"><h2>HAND 企業解決方案 (SZSE:300170)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> HAND Enterprise Solutions Co., Ltd. offers ERP implementation consulting services in China and has a market cap of CN¥19.02 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> HAND 企業解決方案有限公司在中國提供 ERP 實施諮詢服務，市值為 190.2 億人民幣。</p>
</div><p><strong>Operations:</strong> The company specializes in ERP implementation consulting services within China. It focuses on providing tailored solutions to optimize business processes for its clients, contributing significantly to its revenue model.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司專注於在中國提供 ERP 實施諮詢服務，致力於為客户提供量身定製的解決方案，以優化其業務流程，為其收入模式做出重要貢獻。</p>
</div><p>HAND Enterprise Solutions has demonstrated a robust growth trajectory, with earnings forecasted to surge by 26.3% annually, outpacing the broader Chinese market's average of 23.3%. This performance is particularly notable given the firm's recent transition to profitability, which reflects positively on its operational efficiency and market adaptability. The company also maintains a solid commitment to shareholder returns as evidenced by its recent dividend affirmation, distributing a cash dividend of CNY 0.48 per share. Moreover, HAND's strategic focus on R&amp;D is evident from its allocation of significant resources towards innovation—ensuring it remains competitive in the dynamic tech landscape.</p>
<div class="lb-trans"><p>HAND 企業解決方案展現出強勁的增長軌跡，預計年盈利將激增 26.3%，超過中國市場 23.3% 的平均水平。考慮到該公司最近轉向盈利，這一表現尤為顯著，反映了其運營效率和市場適應能力。該公司還堅定致力於股東回報，最近確認分紅，每股現金分紅為 0.48 元人民幣。此外，HAND 在研發方面的戰略重點顯而易見，分配了大量資源用於創新，確保其在動態科技環境中保持競爭力。</p>
</div><ul>
<li>Navigate through the intricacies of HAND Enterprise Solutions with our comprehensive health report here.</li>
<li>Assess HAND Enterprise Solutions' past performance with our detailed historical performance reports.</li>
</ul>
<div class="lb-trans"><ul>
<li>在我們的綜合健康報告中深入瞭解 HAND 企業解決方案的複雜性。</li>
<li>通過我們的詳細歷史業績報告評估 HAND 企業解決方案的過去表現。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/c577163e-dd8c-4766-90c7-04ff8893cfda/chart/revenue-and-expenses-breakdown" alt="" original-src="https://images.simplywall.st/company/c577163e-dd8c-4766-90c7-04ff8893cfda/chart/revenue-and-expenses-breakdown"/></p>
<p>SZSE:300170 Revenue and Expenses Breakdown as at Jul 2025</p>
<div class="lb-trans"><p>截至 2025 年 7 月的 SZSE:300170 收入和支出明細</p>
</div><h2>Hualan Biological Vaccine (SZSE:301207)</h2>
<div class="lb-trans"><h2>華蘭生物疫苗 (SZSE:301207)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增長評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Hualan Biological Vaccine Inc. focuses on the research, development, production, and sale of vaccines in China with a market cap of CN¥11.18 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 華蘭生物疫苗有限公司專注於中國疫苗的研發、生產和銷售，市值為 111.8 億人民幣。</p>
</div><p><strong>Operations:</strong> The company generates revenue primarily through its vaccine products, leveraging its expertise in research and development. Its focus on the Chinese market is supported by a robust production and sales infrastructure.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司主要通過其疫苗產品產生收入，利用其在研發方面的專業知識。其對中國市場的關注得到了強大的生產和銷售基礎設施的支持。</p>
</div><p>Hualan Biological Vaccine is navigating a transformative phase, marked by a robust revenue forecast growth of 36.1% annually, outstripping the broader Chinese market's expansion rate of 12.4%. Despite recent challenges such as a significant earnings dip last year and lower profit margins at 17.9% compared to 35% previously, the company's strategic amendments aim to bolster governance and operational agility. This proactive approach is complemented by an aggressive R&amp;D investment strategy, ensuring Hualan remains at the forefront of innovation in the biotech sector. With earnings expected to surge by 49.8% per year, these initiatives could position Hualan favorably within its competitive landscape.</p>
<div class="lb-trans"><p>華蘭生物疫苗正處於一個轉型階段，預計年收入增長 36.1%，超過中國市場 12.4% 的擴張率。儘管去年面臨顯著的盈利下滑和 17.9% 的較低利潤率（相比之前的 35%），公司的戰略調整旨在增強治理和運營靈活性。這一積極的做法得到了積極的研發投資策略的支持，確保華蘭在生物科技領域保持創新的前沿。預計年盈利將激增 49.8%，這些舉措可能使華蘭在競爭環境中處於有利地位。</p>
</div><ul>
<li>Get an in-depth perspective on Hualan Biological Vaccine's performance by reading our health report here.</li>
<li>Examine Hualan Biological Vaccine's past performance report to understand how it has performed in the past.</li>
</ul>
<div class="lb-trans"><ul>
<li>通過閲讀我們的健康報告，深入瞭解華蘭生物疫苗的表現。</li>
<li>檢查華蘭生物疫苗的過去表現報告，以瞭解其過去的表現。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/85c1c8b5-f8c4-4232-83d4-2d75422da5a7/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/85c1c8b5-f8c4-4232-83d4-2d75422da5a7/chart/earnings-and-revenue-growth"/></p>
<p>SZSE:301207 Earnings and Revenue Growth as at Jul 2025</p>
<div class="lb-trans"><p>深交所：301207 截至 2025 年 7 月的收益和收入增長</p>
</div><h2>Summing It All Up</h2>
<div class="lb-trans"><h2>總結</h2>
</div><ul>
<li>Click this link to deep-dive into the 745 companies within our Global High Growth Tech and AI Stocks screener.</li>
<li>Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools.</li>
<li>Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊此鏈接深入瞭解我們全球高增長科技和人工智能股票篩選器中的 745 家公司。</li>
<li>這些公司是否是您投資策略的一部分？使用 Simply Wall St 將您的持股整合到一個投資組合中，並通過我們全面的分析工具獲得洞察。</li>
<li>Simply Wall St 是您解鎖全球市場趨勢的關鍵，是一款面向前瞻性投資者的免費用户友好應用程序。</li>
</ul>
</div><h2>Searching for a Fresh Perspective?</h2>
<div class="lb-trans"><h2>尋找新視角？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
<li>Find companies with promising cash flow potential yet trading below their fair value.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>用顯示強勁增長潛力的公司來充實您的投資組合，這些公司得到了分析師和管理層的樂觀展望支持。</li>
<li>尋找現金流潛力良好但交易價格低於其公允價值的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>這篇文章由 Simply Wall St 撰寫，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，僅使用無偏見的方法，我們的文章不構成財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
</div>

2025 年 7 月可供投資者探索的高增長科技股